首页> 外国专利> FIBROBLAST GROWTH FACTOR RECEPTORS 1, 2, 3, AND 4 AS TARGETS FOR THERAPEUTIC INTERVENTION

FIBROBLAST GROWTH FACTOR RECEPTORS 1, 2, 3, AND 4 AS TARGETS FOR THERAPEUTIC INTERVENTION

机译:成纤维细胞生长因子受体1、2、3和4作为治疗干预的靶标

摘要

Isolated fibroblast growth factor receptor 1 (“FGFR1”), fibroblast growth factor receptor 2 (“FGFR2”), fibroblast growth factor receptor 3 (“FGFR3”), and fibroblast growth receptor 4 (“FGFR4”) polypeptides and polynucleotides encoding the FGFR1-4 polypeptides, respectively, are provided. Additionally, antibodies, directed to the FGFR1-4 polypeptides and polynucleotides, inclusive of all polymorphic forms and variants thereof, are described. These antibodies either specifically activate the polypeptide or specifically interfere with the activity of the polypeptide. Further provided are methods of treating diseases, such as proliferative diseases, inflammatory diseases, and metabolic disorders, and kits and compositions employing the disclosed compositions. Specifically disclosed is a method of treating tumors in a subject where an antagonist of FGFR1, FGFR2, FGFR3, and/or FGFR4 is administered to the subject.
机译:分离的成纤维细胞生长因子受体1(“ FGFR1”),成纤维细胞生长因子受体2(“ FGFR2”),成纤维细胞生长因子受体3(“ FGFR3”)和成纤维细胞生长受体4(“ FGFR4”)多肽和编码FGFR1的多核苷酸分别提供了-4个多肽。另外,描述了针对FGFR1-4多肽和多核苷酸的抗体,包括其所有多态形式和变体。这些抗体或者特异性地激活多肽或者特异性地干扰多肽的活性。还提供了治疗疾病的方法,例如增生性疾病,炎性疾病和代谢紊乱,以及采用所公开的组合物的试剂盒和组合物。具体公开了一种在受试者中治疗FGFR1,FGFR2,FGFR3和/或FGFR4的拮抗剂的治疗肿瘤的方法。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号